These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35822094)

  • 1. Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
    Ahmad MSZ; Ahmed M; Khedr M; Borgia A; Madden A; Ranganath LR; Kaye S
    JIMD Rep; 2022 Jul; 63(4):351-360. PubMed ID: 35822094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Norman BP; Alsbou M; Imrich R; Gornall M; Sireau N; Gallagher JA; Jackson R
    JIMD Rep; 2022 Jan; 63(1):80-92. PubMed ID: 35028273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
    Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Wilson PJ; Dillon JP; West E; Gallagher JA
    JIMD Rep; 2020 Sep; 55(1):75-87. PubMed ID: 32904992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
    Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
    JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Joint replacement risk is markedly increased in alkaptonuria (AKU) in those with prior arthroplasty.
    Ranganath LR; Khedr M; Norman BP; Hughes JH; Imrich R; Arnoux JB; Olsson B; Rudebeck M; Gallagher JA; Bou-Gharios G
    Mol Genet Metab Rep; 2024 Sep; 40():101097. PubMed ID: 38846518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.
    Khedr M; Judd S; Briggs MC; Hughes AT; Milan AM; Stewart RMK; Lock EA; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 40():31-37. PubMed ID: 28942493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.
    Griffin R; Psarelli EE; Cox TF; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA; Ranganath LR
    Data Brief; 2018 Oct; 20():1620-1628. PubMed ID: 30263914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Norman BP; Bou-Gharios G; Gallagher JA; Gornall M; Jackson R; Imrich R; Rovensky J; Rudebeck M; Olsson B
    Mol Genet Metab Rep; 2022 Mar; 30():100846. PubMed ID: 35242577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
    Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    J Inherit Metab Dis; 2021 May; 44(3):666-676. PubMed ID: 33452825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterising the arthroplasty in spondyloarthropathy in a large cohort of eighty-seven patients with alkaptonuria.
    Ranganath LR; Gallagher JA; Davidson J; Vinjamuri S
    J Inherit Metab Dis; 2021 May; 44(3):656-665. PubMed ID: 33314212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
    Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR
    J Inherit Metab Dis; 2024 Jul; 47(4):664-673. PubMed ID: 38487984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of Parkinson's disease in alkaptonuria.
    Ranganath L; Khedr M; Milan AM; Davison AS; Norman BP; Janssen MCH; Lock E; Bou-Gharios G; Gallagher JA
    JIMD Rep; 2023 Jul; 64(4):282-292. PubMed ID: 37404676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.